Skip to main content

Table 1 Patients’ demographic and clinical characteristics

From: Clinical utility of dynamic chest radiography as an auxiliary tool for atrial fibrillation detection in heart failure: a pilot study

 

All patients

(n = 20)

Sinus rhythm

(n = 17)

Atrial fibrillation

(n = 3)

P

Age, years

67 (50–76)

66 (48–74)

79 (70–80)

0.203

Male

17 (85)

14 (82)

3 (100)

0.430

Body surface area, m2

1.63 (1.49–1.80)

1.58 (1.49–1.79)

1.77 (1.67–1.86)

0.266

NYHA functional class I/II/III

10/9/1

9/7/1

1/2/0

0.666*

Aetiology of HF

    

Ischaemic cardiomyopathy

6 (30)

5 (29)

1 (33)

0.891

Dilated cardiomyopathy

2 (10)

2 (12)

0 (0)

0.531

Hypertrophic cardiomyopathy

1 (5)

1 (6)

0 (0)

0.666

Valvular heart disease

3 (15)

2 (12)

1 (33)

0.334

Hypertensive heart disease

3 (15)

2 (12)

1 (33)

0.334

Cardiac amyloidosis

2 (10)

2 (12)

0 (0)

0.531

Cardiac sarcoidosis

1 (5)

1 (6)

0 (0)

0.666

Anthracycline-induced cardiomyopathy

1 (5)

1 (6)

0 (0)

0.666

Post-myocarditis

1 (5)

1 (6)

0 (0)

0.666

Comorbidity

    

Hypertension

9 (45)

7 (41)

2 (67)

0.413

Diabetes mellitus

7 (35)

6 (35)

1 (33)

0.947

Dyslipidaemia

11 (55)

9 (53)

2 (67)

0.659

Chronic obstructive pulmonary disease

1 (5)

0 (0)

1 (33)

0.014

Medical therapy

    

Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker

12 (60)

10 (59)

2 (67)

0.798

Angiotensin receptor-neprilysin inhibitor

1 (5)

0 (0)

1 (33)

0.014

Beta-blocker

11 (55)

9 (53)

2 (67)

0.659

Mineralocorticoid receptor antagonist

7 (35)

6 (35)

1 (33)

0.947

Sodium-glucose cotransporter 2 inhibitor

5 (25)

4 (24)

1 (33)

0.717

Loop diuretic

13 (65)

10 (59)

3 (100)

0.168

Laboratory measurement

    

Haemoglobin, g/dL

13.0 (10.9–13.7)

12.7 (10.7–13.2)

14.4 (13.8–16.4)

0.063

Sodium, mEq/L

140 (137–141)

140 (137–141)

140 (139–141)

0.871

Albumin, g/dL

4.0 (3.8–4.2)

4.0 (3.7–4.2)

3.8 (3.8–4.0)

0.915

Creatinine, mg/dL

1.05 (0.87–1.29)

0.99 (0.86–1.23)

1.35 (1.32–1.46)

0.026

BNP, pg/mL

209.9 (46.6–396.1)

176.4 (40.8–399.8)

245.4 (226.9–320.1)

0.560

NT-proBNP, pg/mL

1572 (521–2355)

966 (227–2258)

1887 (1779–2444)

0.248

High-sensitivity C-reactive protein, mg/dL

0.08 (0.04–0.53)

0.07 (0.03–0.58)

0.48 (0.26–0.49)

0.779

Electrocardiography

    

Sinus rhythm

17 (85)

17 (100)

0 (0)

< 0.001

Atrial fibrillation

3 (15)

0 (0)

3 (100)

< 0.001

Heart rate, bpm

71 (64–82)

71 (64–81)

70 (45–87)

0.697

Echocardiography

    

LAD, mm

44.4 (42.1–46.9)

44.0 (40.8–46.8)

45.6 (44.7–58.1)

0.289

LVEDD, mm

55.3 (46.5–65.8)

54.0 (45.4–65.8)

61.5 (56.0–67.6)

0.314

LVEF (Teichholz), %

37.6 (25.3–61.0)

44.7 (28.5–60.7)

20.8 (16.5–30.5)

0.101

LVEF (Simpson), %

38.8 (26.3–62.2)

44.7 (26.4–63.0)

35.7 (22.9–36.8)

0.185

E/e′

17.8 (11.0–21.6)

16.1 (10.7–21.5)

21.6 (18.5–23.9)

0.289

Moderate or severe mitral regurgitation

3 (15)

1 (6)

2 (67)

0.006

  1. Data are presented as the median (interquartile range) or n (%)
  2. BNP, brain natriuretic peptide; bpm, beats/minute; E/e′, ratio of early transmitral flow velocity to early diastolic mitral annular velocity; HF, heart failure; LAD, left atrial diameter; LVEDD, left ventricular end-diastolic diameter; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association
  3. *P value was obtained by comparing the number of patients classified as NYHA functional classes I and II with the number classified as NYHA functional class III
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us